Jupiter Neurosciences financials
$2.58+2.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $21.8K | $0.00 |
| Gross profit | $17.6K | $0.00 |
| Gross margin | 80.6% | — |
| Operating income | -$8.9M | -$3.1M |
| Net income | -$8.6M | -$2.4M |
| Net margin | −39662.8% | — |
| Diluted EPS | $-18.75 | $-6.00 |
| EBITDA | -$8.1M | -$3.0M |
| Operating cash flow | -$5.4M | -$3.9M |
| Free cash flow | -$5.4M | -$3.9M |
| Diluted shares | 0.5M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.8M | $3.8M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $5.3M | $1.1K |
| Total assets | $5.6M | $6.2M |
| Total liabilities | $7.4M | $2.0M |
| Shareholders' equity | -$1.8M | $4.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology